NuVasive announced that the US Food and Drug Administration (FDA) has approved the NuVasive Simplify Cervical Artificial Disc (Simplify Disc) for two-level cervical …
NuVasive Inc expanded its partnership with the International Spine Study Group Foundation (ISSGF) with the launch of two new clinical studies. These studies …
Spine tech stock NuVasive (NUVA) has announced preliminary results for the second quarter 2020, sending shares 5% higher in Monday’s after-hours trading. Despite a …
Jefferies analyst Raj Denhoy reiterates his Buy rating on NuVasive, Inc. (NASDAQ:NUVA) with a price target of $72.
In a research report issued today, Brean Capital analyst Jason Wittes maintained a Buy rating on NuVasive Inc (NASDAQ:NUVA) with a $53 price target, after …
